Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed Impella 2.5 and 5.0:

This article was originally published in Clinica

Executive Summary

Abiomed has received Canadian approval for its Impella 2.5 and Impella 5.0 ventricular cardiac assist devices for maintaining circulatory support. The devices are inserted minimally invasively into the left ventricle, where they help pump blood in heart failure patients. The Danvers, Massachusetts company has already CE marked the Impella 2.5 for sale in Europe, and Abiomed has now completed enrolment in a pilot study of the technology in the US. The Impella 5.0, which can also be inserted surgically, is CE-marked too, and is in pilot studies in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel